KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Debt to Equity (2016 - 2020)

Historic Debt to Equity for Nektar Therapeutics (NKTR) over the last 10 years, with Q1 2020 value amounting to $0.39.

  • Nektar Therapeutics' Debt to Equity rose 15922.04% to $0.39 in Q1 2020 from the same period last year, while for Mar 2020 it was $0.39, marking a year-over-year increase of 15922.04%. This contributed to the annual value of $0.36 for FY2019, which is 14887.62% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Debt to Equity of $0.39 as of Q1 2020, which was up 15922.04% from $0.36 recorded in Q4 2019.
  • In the past 5 years, Nektar Therapeutics' Debt to Equity ranged from a high of $72.16 in Q2 2017 and a low of -$880.47 during Q1 2016
  • Over the past 5 years, Nektar Therapeutics' median Debt to Equity value was $0.17 (recorded in 2019), while the average stood at -$46.96.
  • Its Debt to Equity has fluctuated over the past 5 years, first tumbled by 5455195.53% in 2016, then soared by 126766.84% in 2017.
  • Nektar Therapeutics' Debt to Equity (Quarter) stood at $2.76 in 2016, then grew by 1.06% to $2.79 in 2017, then plummeted by 94.85% to $0.14 in 2018, then skyrocketed by 148.88% to $0.36 in 2019, then increased by 9.71% to $0.39 in 2020.
  • Its last three reported values are $0.39 in Q1 2020, $0.36 for Q4 2019, and $0.17 during Q3 2019.